The Experts Group on Inositol in Basic and Clinical Research (EGOI) was conceived to address and clarify some important issues concerning the physiological role and the hypothetical use of Inositols in a number of biological and medical fields, including gynecology, reproduction, cancer, neurology, metabolic and endocrinological disorders.
The group brings together several international personalities, researchers and opinion leaders, skilled in the field of inositol physiology and therapy, with the aim to discuss and share scientific contents relating to their own expertise in the field.
Scientific evidence suggests beneficial effects of Inositol – altogether with its natural occurring 9 stereoisomers – both in prevention and in the clinical management of many different diseases.
In particular, investigations carried out on Myo- and D-chiro-inositol – two putative second messengers of insulin – provided in gathering very provocative and relevant data on the inositol physiological functions.
As a result, inositol involvement in a wide range of ailments – including polycystic ovary syndrome (PCOS), insulin resistance (IR), metabolic syndrome, gestational diabetes mellitus (GDM) and neural tube defects (NTDs) – characterized by deregulation of insulin signaling, has been shown.
Inositol has recently acquired a prominent place in Oncological and Cardiological studies, namely regarding an intertwined set of networked pathways, which are finely tuned by inositol supplementation. Inositol phosphates derivatives, especially those downstream the activation of specific inositol kinases, play critical roles in chromatin remodeling and DNA methylation. Overall, the participation of those metabolites seems to exert unexpected key functions during morphogenesis and cell fate commitment, in both natural and pathological processes.
Thereby, inositol-related fields are becoming a hot topic. However, despite that data and results on the use of Inositols are continuously increasing, some key concepts need to be addressed, mainly concerning the proper use and combination of inositol isomers in different clinical settings.
A specific case in point is represented by the most appropriate ratio between the two main isoforms – myo- and D-chiro-inositol – that should be achieved in pharmacological delivery in order to maintain and/or restore the physiological balance.
EGOI focus its activity in fostering advanced studies and scientific debate on these arguments, by enhancing the cooperation and scientific networking among scientists from different countries.